152 related articles for article (PubMed ID: 25388940)
1. Phase 2 study of CT-322, a targeted biologic inhibitor of VEGFR-2 based on a domain of human fibronectin, in recurrent glioblastoma.
Schiff D; Kesari S; de Groot J; Mikkelsen T; Drappatz J; Coyle T; Fichtel L; Silver B; Walters I; Reardon D
Invest New Drugs; 2015 Feb; 33(1):247-53. PubMed ID: 25388940
[TBL] [Abstract][Full Text] [Related]
2. Phase I and pharmacokinetic study of CT-322 (BMS-844203), a targeted Adnectin inhibitor of VEGFR-2 based on a domain of human fibronectin.
Tolcher AW; Sweeney CJ; Papadopoulos K; Patnaik A; Chiorean EG; Mita AC; Sankhala K; Furfine E; Gokemeijer J; Iacono L; Eaton C; Silver BA; Mita M
Clin Cancer Res; 2011 Jan; 17(2):363-71. PubMed ID: 21224368
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma.
Batchelor TT; Duda DG; di Tomaso E; Ancukiewicz M; Plotkin SR; Gerstner E; Eichler AF; Drappatz J; Hochberg FH; Benner T; Louis DN; Cohen KS; Chea H; Exarhopoulos A; Loeffler JS; Moses MA; Ivy P; Sorensen AG; Wen PY; Jain RK
J Clin Oncol; 2010 Jun; 28(17):2817-23. PubMed ID: 20458050
[TBL] [Abstract][Full Text] [Related]
4. Randomized phase II study of axitinib versus physicians best alternative choice of therapy in patients with recurrent glioblastoma.
Duerinck J; Du Four S; Vandervorst F; D'Haene N; Le Mercier M; Michotte A; Van Binst AM; Everaert H; Salmon I; Bouttens F; Verschaeve V; Neyns B
J Neurooncol; 2016 May; 128(1):147-155. PubMed ID: 26935577
[TBL] [Abstract][Full Text] [Related]
5. Phase 1/2 trial of temsirolimus and sorafenib in the treatment of patients with recurrent glioblastoma: North Central Cancer Treatment Group Study/Alliance N0572.
Schiff D; Jaeckle KA; Anderson SK; Galanis E; Giannini C; Buckner JC; Stella P; Flynn PJ; Erickson BJ; Schwerkoske JF; Kaluza V; Twohy E; Dancey J; Wright J; Sarkaria JN
Cancer; 2018 Apr; 124(7):1455-1463. PubMed ID: 29313954
[TBL] [Abstract][Full Text] [Related]
6. A phase 2 trial of verubulin for recurrent glioblastoma: a prospective study by the Brain Tumor Investigational Consortium (BTIC).
Chamberlain MC; Grimm S; Phuphanich S; Recht L; Zhu JZ; Kim L; Rosenfeld S; Fadul CE;
J Neurooncol; 2014 Jun; 118(2):335-343. PubMed ID: 24740196
[TBL] [Abstract][Full Text] [Related]
7. Randomized phase II trial comparing axitinib with the combination of axitinib and lomustine in patients with recurrent glioblastoma.
Duerinck J; Du Four S; Bouttens F; Andre C; Verschaeve V; Van Fraeyenhove F; Chaskis C; D'Haene N; Le Mercier M; Rogiers A; Michotte A; Salmon I; Neyns B
J Neurooncol; 2018 Jan; 136(1):115-125. PubMed ID: 28988341
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of erlotinib in first-relapse glioblastoma: a phase II open-label study.
Yung WK; Vredenburgh JJ; Cloughesy TF; Nghiemphu P; Klencke B; Gilbert MR; Reardon DA; Prados MD
Neuro Oncol; 2010 Oct; 12(10):1061-70. PubMed ID: 20615922
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of tivozanib, an oral VEGFR inhibitor, in patients with recurrent glioblastoma.
Kalpathy-Cramer J; Chandra V; Da X; Ou Y; Emblem KE; Muzikansky A; Cai X; Douw L; Evans JG; Dietrich J; Chi AS; Wen PY; Stufflebeam S; Rosen B; Duda DG; Jain RK; Batchelor TT; Gerstner ER
J Neurooncol; 2017 Feb; 131(3):603-610. PubMed ID: 27853960
[TBL] [Abstract][Full Text] [Related]
10. Phase I study of AEE788, a novel multitarget inhibitor of ErbB- and VEGF-receptor-family tyrosine kinases, in recurrent glioblastoma patients.
Reardon DA; Conrad CA; Cloughesy T; Prados MD; Friedman HS; Aldape KD; Mischel P; Xia J; DiLea C; Huang J; Mietlowski W; Dugan M; Chen W; Yung WK
Cancer Chemother Pharmacol; 2012 Jun; 69(6):1507-18. PubMed ID: 22392572
[TBL] [Abstract][Full Text] [Related]
11. Anti-tumor effect of CT-322 as an adnectin inhibitor of vascular endothelial growth factor receptor-2.
Mamluk R; Carvajal IM; Morse BA; Wong H; Abramowitz J; Aslanian S; Lim AC; Gokemeijer J; Storek MJ; Lee J; Gosselin M; Wright MC; Camphausen RT; Wang J; Chen Y; Miller K; Sanders K; Short S; Sperinde J; Prasad G; Williams S; Kerbel R; Ebos J; Mutsaers A; Mendlein JD; Harris AS; Furfine ES
MAbs; 2010; 2(2):199-208. PubMed ID: 20190562
[TBL] [Abstract][Full Text] [Related]
12. A phase I study of cediranib in combination with cilengitide in patients with recurrent glioblastoma.
Gerstner ER; Ye X; Duda DG; Levine MA; Mikkelsen T; Kaley TJ; Olson JJ; Nabors BL; Ahluwalia MS; Wen PY; Jain RK; Batchelor TT; Grossman S
Neuro Oncol; 2015 Oct; 17(10):1386-92. PubMed ID: 26008604
[TBL] [Abstract][Full Text] [Related]
13. Phase II trial of ponatinib in patients with bevacizumab-refractory glioblastoma.
Lee EQ; Muzikansky A; Duda DG; Gaffey S; Dietrich J; Nayak L; Chukwueke UN; Beroukhim R; Doherty L; Laub CK; LaFrankie D; Fontana B; Stefanik J; Ruland S; Caruso V; Bruno J; Ligon K; Reardon DA; Wen PY
Cancer Med; 2019 Oct; 8(13):5988-5994. PubMed ID: 31444999
[TBL] [Abstract][Full Text] [Related]
14. Phase 2 study of bosutinib, a Src inhibitor, in adults with recurrent glioblastoma.
Taylor JW; Dietrich J; Gerstner ER; Norden AD; Rinne ML; Cahill DP; Stemmer-Rachamimov A; Wen PY; Betensky RA; Giorgio DH; Snodgrass K; Randall AE; Batchelor TT; Chi AS
J Neurooncol; 2015 Feb; 121(3):557-63. PubMed ID: 25411098
[TBL] [Abstract][Full Text] [Related]
15. Targeted therapy with bevacizumab and erlotinib tailored to the molecular profile of patients with recurrent glioblastoma. Preliminary experience.
D'Alessandris QG; Montano N; Cenci T; Martini M; Lauretti L; Bianchi F; Larocca LM; Maira G; Fernandez E; Pallini R
Acta Neurochir (Wien); 2013 Jan; 155(1):33-40. PubMed ID: 23132371
[TBL] [Abstract][Full Text] [Related]
16. Clinical activity and safety of atezolizumab in patients with recurrent glioblastoma.
Lukas RV; Rodon J; Becker K; Wong ET; Shih K; Touat M; Fassò M; Osborne S; Molinero L; O'Hear C; Grossman W; Baehring J
J Neurooncol; 2018 Nov; 140(2):317-328. PubMed ID: 30073642
[TBL] [Abstract][Full Text] [Related]
17. Phase II open-label study of nintedanib in patients with recurrent glioblastoma multiforme.
Muhic A; Poulsen HS; Sorensen M; Grunnet K; Lassen U
J Neurooncol; 2013 Jan; 111(2):205-12. PubMed ID: 23184145
[TBL] [Abstract][Full Text] [Related]
18. Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial.
Wen PY; Touat M; Alexander BM; Mellinghoff IK; Ramkissoon S; McCluskey CS; Pelton K; Haidar S; Basu SS; Gaffey SC; Brown LE; Martinez-Ledesma JE; Wu S; Kim J; Wei W; Park MA; Huse JT; Kuhn JG; Rinne ML; Colman H; Agar NYR; Omuro AM; DeAngelis LM; Gilbert MR; de Groot JF; Cloughesy TF; Chi AS; Roberts TM; Zhao JJ; Lee EQ; Nayak L; Heath JR; Horky LL; Batchelor TT; Beroukhim R; Chang SM; Ligon AH; Dunn IF; Koul D; Young GS; Prados MD; Reardon DA; Yung WKA; Ligon KL
J Clin Oncol; 2019 Mar; 37(9):741-750. PubMed ID: 30715997
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of bevacizumab and temsirolimus combination therapy for recurrent glioblastoma multiforme.
Lassen U; Sorensen M; Gaziel TB; Hasselbalch B; Poulsen HS
Anticancer Res; 2013 Apr; 33(4):1657-60. PubMed ID: 23564811
[TBL] [Abstract][Full Text] [Related]
20. Open-Label Phase II Evaluation of Imatinib in Primary Inoperable or Incompletely Resected and Recurrent Glioblastoma.
Sautter L; Hofheinz R; Tuettenberg J; Grimm M; Vajkoczy P; Groden C; Schmieder K; Hochhaus A; Wenz F; Giordano FA
Oncology; 2020; 98(1):16-22. PubMed ID: 31514200
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
